 |
afatinib |
|---|---|
| Trade Name | Gilotrif(R) |
| Orphan Indication | Malignant brain and central nervous system tumors |
| USA Market Approval | USA |
| USA Designation Date | 2014-06-04 00:00:00 |
| Sponsor | Boehringer Ingelheim Pharmaceuticals, Inc.;900 Ridgebury Road, P. O. Box 368;Ridgefield, Connecticut, 06877 |
